Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): In vitro and in vivo enhancement of radiation response

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 3869-3878

  Loriot, Yohann ^a,c   Mordant, Pierre ^a,c   Brown, Bob D ^b   Bourhis, Jean ^a   Soria, Jean Charles ^a,c   Deutsch, Eric ^a,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Genta Inc   (United States)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Oblimersen; Radiation; Small cell lung cancer

Indexed keywords

OBLIMERSEN; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG SMALL CELL CANCER; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650244025     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Letai AG: Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer S: 121-132, 2008.
3. Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339, 1994.
4. Rupnow BA, Murtha AD, Alarcon and Giaccia AJ and Knox SJ: Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res 58: 1779-1784, 1998.
5. Boyle P, d'Onofrio A, Maisonneuve P Severi G, Robertson C, Tubiana M and Veronesi U: Measuring progress against Cancer in Europe. Has the 15% decline targeted for 2000 come about? Ann Oncol 14: 1312-1325, 2003.
6. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results Database. J Clin Oncol 24: 4539-4544, 2006.
7. Jackman DM and Johnson BE: Small-cell lung cancer. Lancet 366: 1385-1396, 2005.
8. Spira A and Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392, 2004.
9. Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC, Miller AA, Thomas CR Jr and Blackstock AW: Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer 64: 226-231, 2009.
10. Brambilla E, Negoescu A, Gazzeri S, Gazzeri S, Lantuejoul S, Moro D, Brambilla C and Coll JL: Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors Am J Pathol 149: 1941-1952, 1996.
11. Sartorius UA and Krammer PH: Up-regulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97: 584-592, 2002.
12. Sirzén F, Zhivotovsky B, Nilsson A, Nilsson A, Bergh J and Lewensohn R: Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities. Anticancer Res 18: 695-699, 1998.
13. Butterfield L, Storey B, Maas L and Heasley LE: c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem 272: 10110-10116, 1997.
14. Reed JC, Stein C, Subasinghe C, Subasinghe C, Haldar S, Croce CM, Yum S and Cohen J: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50: 6565-6570, 1990.
15. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F and Cotter FE: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 1812-1823, 2000.
16. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD and Rosser CJ: Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther 6: 101-111, 2007.
17. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G and Deutsch E: Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27: 3244-55, 2008.
18. Sørensen M and Felip E; ESMO Guidelines Working Group. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4): 71-2, 2009.
19. Shivapurkar N, Reddy J, Chaudhary PM and Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem 88: 885-898, 2003.
20. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-9, 2006
21. Banasiak D, Barnetson AR, Odell RA, Mameghan H and Russell PJ: Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Investig 7: 77-85, 1999.
22. Grossfield GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM and Carroll PR: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 159: 1437-1443, 1998.
23. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD and White RW: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51: 346-351, 1998.
24. Loomis R, Carbone R, Reiss M and Lacy J: Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Clin Cancer Res 9: 1931-1939, 2003.
25. + nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer 119: 309-316 2006.
26. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, Minna JD and Pollack JR: Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25: 130-138, 2006.
27. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, Bastianutto C and Liu FF. Combination Bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131-8144, 2005.
28. Zeitlin BD, Zeitlin IJ and Nör JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 26: 4180-4188, 2008.
29. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM and Haluska FG; Oblimersen Melanoma Study Group: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745, 2006.
30. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M and Vokes EE; Randomized phase II study of carboplatin and etoposide with or without the Bcl-2 antisense oligonucleotide oblimersen for extensive-stage small cell lung cancer: CALGB 30103. J Clin Oncol 26: 870-876, 2008.
31. Pisano M, Baldinu P, Sini MC, Ascierto PA, Tanda F and Palmieri G: Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. Ann Oncol 19: 2092-2093, 2008.
32. Loriot Y, Mordant P and Deutsch E. Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both? Ann Oncol 20: 596-597, 2009.
33. Jansen B and Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol 3: 672-683, 2002.
34. Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454, 2007.
35. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN and Rudin CM: Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer Cancer Res 68: 2321-2328, 2008.
36. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC and Andreeff M: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388, 2006.
37. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR and Kumar S: ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21: 1549-1560, 2007.